

EPIC Translation Repository

These translations and validations of EPIC were not created by our team at the University of Michigan. We are simply providing them as a resource for those who might be interested in using them. Therefore, if you would like more information on any of these translations and validations, please reach out to the primary authors listed below.

Translation	Language	Dialect/ Country	Version of EPIC	Primary Author	Translation Group	Validation Citation	Validation Methods
Link	Chinese	Cantonese	EPIC 50	Tsz Kin Lee	Department of Radiation Oncology, Abbotsford Cancer Centre, British Columbia Cancer Agency <i>British Columbia, Canada</i>	2	2 forward translations, combined to 1, back translation
Link	Chinese	Traditional Chinese	EPIC 26	Wendy W. T. Lam	The University of Hong Kong <i>Pok Fu Lam, Hong Kong</i>	1	Forward translation, review, back translation, amendments, repeated until English versions had matched meanings
Link	Dutch	Netherlands	EPIC 50	Julia vanTol- Geerdink	Department of Radiation Oncology/Urology/Public Health, Radboud University Medical Centre <i>Nijmegen, The Netherlands</i>	3, 4	Forward translation, discussion until consensus
Link	Filipino	Philippines	EPIC 50	Warren Bacorro	University of Santo Tomas, Venavides Cancer Institute, <i>Manila, Philippines</i>	15	Forward and back-translation, expert panel review, pilot testing and focus group discussion, and revision
Link	French	Belgium	EPIC 26	MAPI Research Trust	MAPI Research Trust	6	2 forward translation or review/adaptation, back translation, 5 cognitive interviews, international harmonisation
Link	French	Canada	EPIC 26	Éric Vigneault	CHU de Québec-Université Laval Research Centre <i>Quebec City, QC, Canada</i>	5	Translated EPIC 26 to French, 2 translators assessed and suggested alternative wording, translated EPIC 50 to French, one of two versions (EPIC 26/50) or combination of each item was kept, repeated process but with Canadian French translators
Link	French	Canada	EPIC 50	Éric Vigneault	CHU de Québec-Université Laval Research Centre <i>Quebec City, QC, Canada</i>	5	Translated EPIC 26 to French, 2 translators assessed and suggested alternative wording, translated EPIC 50 to French, one of two versions (EPIC 26/50) or combination of each item was kept, repeated process but with Canadian French translators

Link	French	France	EPIC 26	MAPI Research Trust	MAPI Research Trust	7	2 forward translation or review/adaptation, back translation, 5 cognitive interviews, international harmonisation
Link	German	Germany	EPIC 26	Nora T. Sibert	German Cancer Society <i>Berlin, Germany</i>	8	Translation and retranslation, inaccuracies discussed, consensus reached, revised by doctors, tested by patients
Link	German	Germany, Austria, Switzerland	EPIC 50	Martin H. Umbeh	University of Zurich <i>Zurich, Switzerland</i>	9	Forward translations, pilot testing, back translation, pilot testing, validation process
Link	Korean	Korea	EPIC 50	Sung Won Lee	Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine <i>Seoul, Korea</i>	10	2 forward translations, combined to one, back translation, amendments
Link	Norwegian	Norway	EPIC 26	Sophie D. Fosså	Oslo University Hospital <i>Oslo, Norway</i>	14	Translated, tested & corrected, back translated, compared with English US version
Link	Portuguese	Brazil	EPIC 50	Cassio Andreoni	Department of Urology, Escola Paulista de Medicina da Universidade Federal de São Paulo, EPM/UNIFESP - <i>Sao Paulo, SP, Brazil</i>	16	Initial translation, synthesis of translation, board committee review and back translation
Link	Portuguese	Brazil	EPIC-CP	Danilo B. Lourenço	Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, Sala 303, Bloco A1, <i>Sao Paulo, SP, Brazil</i> . 2 Institut Mutualiste Montsouris, <i>Paris, France</i> . 3 Beth Israel Medical Center, Harvard Medical School, <i>Boston, MA, USA</i>	17	Cronbach's alpha coefficient to evaluate internal consistency. The EPIC-CP domains were compared before surgery, and 6 months and 12 months after surgery. Statistical analyses were performed using the Student's <i>t</i> test, and Wilcoxon and Friedman tests, with <i>p</i> values < 0.05 considered significant.
Link	Spanish	Spain	EPIC 26	Montserrat Ferrer Forés	Unidad de Investigación en Servicios Sanitarios, IMIM-Hospital del Mar <i>Barcelona, España</i> .	12	Translation and back-translation
Link	Spanish	Spain	EPIC 50	Montserrat Ferrer Forés	Unidad de Investigación en Servicios Sanitarios, IMIM-Hospital del Mar <i>Barcelona, España</i> .	12	Translation and back-translation
Link	Spanish	Spain	EPIC-CP	Jae Lee	University of Michigan <i>Ann Arbor, MI</i>	13	Translation and back-translation
Link	Spanish	US	EPIC 26	Donna L. Berry	The Phyllis F. Cantor Center, Dana-Farber Cancer Institute <i>Boston, MA, USA</i>	11	Forward and backtranslation by 3 translators (2 Mexican, 1 Puerto Rican), review by bilingual study staff, discussion with translators staff and PI

Link	Turkish	Turkey	EPIC-CP	Ayşe GÖKTAŞ	Ege University Nursing Faculty <i>Izmir, Turkey</i>		
----------------------	---------	--------	---------	-------------	--	--	--

Citations

1. Lam WWT, Tse MA, Ng CNL, Chung EKM, Fielding R. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer. *Journal of pain and symptom management*. 2017;53(6):1085-1090.
2. Lee TK, Poon DMC, Ng ACF, et al. Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite. *Asia-Pacific journal of clinical oncology*. 2018;14 Suppl 1:10-15.
3. Venderbos LDF, Aluwini S, Roobol MJ, et al. Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. *Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation*. 2017;26(6):1635-1645.
4. van Tol-Geerdink JJ, Leer JW, van Oort IM, et al. Quality of life after prostate cancer treatments in patients comparable at baseline. *British journal of cancer*. 2013;108(9):1784-1789.
5. Vigneault E, Savard J, Savard MH, et al. Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population. *Canadian Urological Association journal = Journal de l'Association des urologues du Canada*. 2017;11(12):404-410.
6. French (Belgium) MAPI Research Trust Documentation.
7. French (France) MAPI Research Trust Documentation.
8. Sibert NT, Dieng S, Oesterle A, et al. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer. *World journal of urology*. 2019;10.1007/s00345-00019-02949-00347.
9. Umbehre MH, Bachmann LM, Poyet C, et al. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation. *Health and quality of life outcomes*. 2018;16(1):36.
10. Chung KJ, Kim JJ, Lim SH, Kim TH, Han DH, Lee SW. Development and validation of the Korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment. *Korean J Urol*. 2010;51(9):601-612.
11. Berry DL, Halpenny B, Bosco JLF, Bruyere J, Jr., Sanda MG. Usability evaluation and adaptation of the e-health Personal Patient Profile-Prostate decision aid for Spanish-speaking Latino men. *BMC medical informatics and decision making*. 2015;15:56.
12. Ferrer M, Garin O, Pera J, et al. Evaluation of the quality of life of patients with localized prostate cancer: validation of the Spanish version of the EPIC. *Med Clin (Barc)*. 2009;132(4):128-135.
13. Lee JY, Daignault-Newton S, Heath G, et al. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. *Int J Radiat Oncol Biol Phys*. 2016;96(4):770-777.
14. Fosså SD, Storås AH, Steinsvik EA, et al. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26). *Scand J Urol*. 2016;50(4):280-285.
15. Bacorro W, Tordesillas D, Dumago M, et al. Development and pilot testing of the expanded prostate index composite-Filipino version (EPIC-F). *Asia-Pac J Clin Oncol*. 2022;1-8.
16. Alves E, Medina R, Andreoni C. Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy. *Int Braz J Urol*. 2013;39(3):344-352.
17. Lourenço D, Amaral B, Alfer-Junior W, et al. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution. *BMC Urol*. 2020:163.